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Copyright © 2009 JCBN Summary To evaluate the latent risk of acidosis in commercially available total parenteral
nutrition (TPN) products, three types of commercially available TPN products were compared
in postoperative patients. Sixty-four hospitalized patients with gastro-intestinal disease who
undertook curative gastro intestinal resection were studied prospectively and administered
with TPN solutions. Three types of commercially available TPN products were assigned
randomly to eligible patients. Serial studies of blood acid-base status, serum electrolytes, and
urinary acid-base status were conducted in the three groups administered with different TPN
solutions. Patients received appropriate electrolytic solutions on the operation day and TPN
solution from 2 to 7 days after operation. There were no differences among any of the serum
electrolytes in the three groups. In one group, urinary pH decreased slightly and urinary net
acid excretion (NAE) increased significantly after administration. This TPN product contains
about 40 mEq/L of non-metabolizable acid to avoid the Maillard reaction that produces a
complex of glucose and amino acids. Urinary NAE did not change in the other two groups.
These TPN products do not use non-metabolizable acid to adjust pH. The present results
suggest that the non-metabolizable acid may be a risk factor of metabolic acidosis.
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Introduction
It is well known that malnutrition generates a predisposi-
tion for postoperative complications, increased incidence
of infection [1], and prolonged hospital stays [2]. Metabolic
disturbances occur in malnourished patients undergoingThe Latent Risk of Acidosis in TPN Products
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major surgery and patients with total parenteral nutrition
(TPN) [3, 4]. Acid-base imbalance, i.e., metabolic acidosis
resulting from infusates of intravenous nutrition, is observed
frequently during TPN therapy [5]. Further acidosis occurs
because of metabolic abnormalities, such as thiamine
deficiency, and an excess of lactic acid induced by the bolus
injection of D-fructose, as well as an excess infusion of
anionic components such as chloride salts provided by the
administration of synthetic L-amino acids [6–8]. Moreover,
acidosis could be related to either the excess amount of
titratable acidity in the infusates or hydrogen ions released
by the metabolism of nitrogen sources [9]. The problem may
be overcome by the use of thiamine hydrochloride, manage-
ment of the infusion rate, or adding free salts or acetate of
cationic amino acid to the preparation [1]. However, even
with such interventions hyperchloremic metabolic acidosis
has been reported during TPN therapy in Japan [10]. Pre-
viously, it was reported that the acid load with hydrochloric
acid in TPN solutions may cause severe hyperchloremic
metabolic acidosis in rabbits [11], although acetic acid may
not produce acidemia for patients, because hydrogen ions
from the acetic acid are neutralized by bicarbonate ions
generated from the metabolism of acetate ions. However,
this hypothesis has not yet been proven by clinical research.
In addition, the regulation of the kind or the amount of acid
for adjusting the pH is not prescribed by the guidelines of
the American Society for Parenteral and Enteral Nutrition
(ASPEN) or the Japanese Society for Parenteral and Enteral
Nutrition (JSPEN).
This study investigated the effects of three types of
commercial TPN products on plasma acid-base balance.
Materials and Methods
Study population
The study was approved by the institutional review board
of Nagoya University Hospital, and the patients gave written
informed consent before enrollment. It was assumed that
the annual incidence of acidosis was lower than 5%. In this
situation, the sample size was calculated by the coordinator
of the Critical Appraisal Skills Program JAPAN (CASPjp:
http://caspjp.umin.ac.jp). Patients with gastrointestinal
carcinoma who had undergone curative resection, such as
gastrectomy, proctocolectomy, or cholecystectomy, and were
admitted to the first surgical unit of Nagoya University
Hospital were enrolled. Because patients with renal dysfunc-
tion may have an increased risk of acidosis, those with renal
insufficiency (50 mL/min: calculated creatinine clearance
using the Cockcroft-Gault formula) were excluded. Patients
with metabolic acidosis or pulmonary complications were
also excluded.
Nutritional management
All patients were managed according to a standard
treatment protocol. Central venous catheters were placed
and all patients received a crystalloid infusion (4.5%
dextrose and 0.2% sodium chloride fluid: Solita T3®
Ajinomoto Pharmaceuticals) before their operations. After
the operation, eligible patients were administered TPN
solutions. The compositions of the three TPN solutions used
in this study are shown in Table 1, and these were based on
the guidelines of ASPEN and JSPEN.
TPN product randomization
After written consent was obtained from the patients
before operation, the attending physician called the CASPjp
call center and the TPN products were assigned randomly
using a computer-generated random number. Sixty-four
patients who had undergone curative resection were random-
ized into the three TPN product groups. The TPN solutions
used were three general commercial products: Aminotoripa®
(AMINO: Branched chain amino acid (BCAA) rich solution
with glucose, fructose, and xylitol solution in a separate
cavity bag; Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan),
Table 1. The composition of the three TPN solutions
AMINO: Branched chain amino acid (BCAA) rich solution and
glucose, fructose and xylitol solution in a separate cavity bag;
Aminotoripa®; PN: Milk composition amino acid solution and
glucose solution contained in a separate cavity bag; PNtwin®; UNI:
BCAA rich solution and glucose solution in same cavity bag;
Unicaliq®
AMINO PN UNI
N+ (mEq/L) 38.9 45.5 40
K+ (mEq/L) 30 27.3 27
Mg2+ (mEq/L) 5.6 5.5 6
Ca2+ (mEq/L) 5.6 7.3 6
Cl− (mEq/L) 38.9 45.5 59
SO42− (mEq/L) 5.6 5.5
Acetate− (mEq/L) 60 36.4 10
Gluconate− (mEq/L) 5.6 7.3 6
Lactate− (mEq/L) — — 35
Malate2− (mEq/L) — — 17
P (mmol/L) 6.7 7.3 8.1
Zn (μmol/L) 10 18.2 20
Glucose (g/L) 111.3 163.6 175
Fructose (g/L) 55.3 — —
Xylitol (g/L) 28 — —
Total free amino acid (g/L) 33.3 27.3 30
pH 5.56 5.1 4.36
Titratable acidity (mEq/L) 24.3 31.9 44.1
Sodium sulfite (g/L) 0.4 0.04 0.48
HCL(mEq/L) — — 35.1–39.1K. Kato et al.
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PNtwin® (PN: Milk composition amino acid solution and
glucose solution contained in a separate cavity bag;
Ajinomoto Pharma Co., Ltd., Tokyo, Japan), and Unicaliq®
(UNI: BCAA rich solution and glucose solution in same
cavity bag; Terumo Corp., Tokyo, Japan). Patients received
appropriate electrolytic solutions on operation day and TPN
solution from 2 to 7 days after operation. All patients
received multivitamins during this study. Blood and urine
samples were collected before operation and 1, 3, 5, and 7
days after operation. Serum electrolytes, creatinine, blood
urea nitrogen (BUN), lactic acid, pyruvic acid, and blood
acid-base status were calculated by using standard auto-
mated laboratory techniques. Twenty-four hour urine
collections for the measurements of urine electrolytes, pH,
creatinine, and urinary NAE were also performed. Urinary
NAE was determined by a titrimetric method [12] and was
the sum of titratable acid and ammonium concentrations
minus the bicarbonate concentration. The titratable endpoint
pH was 7.40 at 0 Pa as a PCO2.
Outcome measures
This randomized clinical study was conducted to discover
the acidosis risk of TPN therapy, and the primary outcome
measure was acidosis as an adverse event. However,
considering the patients’ safety, it was difficult to measure
the harm of TPN therapy using a randomized clinical study
method. Therefore, this study initially evaluated the acidosis
risk in animal subjects, and urinary acid excretion was
confirmed as a risk factor of acidosis. NAE was correlative
with arterial blood pH (p<0.0001). Thus, urinary total acid
excretion used as a surrogate outcome of the acidosis risk
during TPN therapy.
Statistical analysis
Efficacy was analyzed according to the intention to treat
approach. All statistical analyses were performed using
StatView for Windows software (Version 5.0, SAS Institute,
Cary, NC). All data were presented as means ± s.e. Student’s
t test was used for the comparison of data; a p value of less
than 0.05 was considered statistically significant.
Results
Of the 76 patients in the surgical ward who received
curative operations during the study period, 12 were
excluded because of renal insufficiency. Sixty-four eligible
patients were assigned randomly to the three groups. The
demographics for each group were similar (Table 2).
Consent was sought from the 64 eligible patients; all patients
agreed to participate in this study. Twenty one, 22, and 21 of
the 64 patients were allocated to the AMINO, PN, and UNI
groups, respectively. The three groups of patients showed no
important differences in baseline characteristics. No patient
was withdrawn from the study after randomization. All
patient data were included in this study.
The time courses of plasma pH, HCO3−, pCO2, and blood
base excess (BE) levels in the patients after administration
of the TPN solutions are shown in Figure 1. The pH of
arterial blood increased significantly in the AMINO and PN
group after administration. The pCO2 of arterial blood
decreased significantly in the AMINO and PN group at 6
days after administration compared with postoperative day
(POD) 1. The HCO3− concentration of arterial blood
increased significantly in the PN group 1 day after adminis-
tration. BE increased significantly in the AMINO and PN
groups 1 day after administration. There were no significant
differences in anion gap among the three groups during the
Table 2. The characteristics of patients at entry to the study
Data are shown as mean ± s.e. Creatinine clearance calculated by using the Cockcroft–Gault formula.
Characteristic
AMINO 
(n = 21)
PN 
(n = 22)
UNI 
(n =2 1 )
Age (years) 60.5 ± 2.6 55.7 ± 2.9 62.1 ± 2.6
Height (cm) 162.9 ± 2.0 161.5 ± 1.7 157.7 ± 1.8
Weight (kg) 69.7 ± 2.0 56.9 ± 2.1 53.2 ± 2.5
Serum creatinine (mg/dL) 0.83 ± 0.04 0.80 ± 0.04 0.76 ± 0.05
Creatinine clearance (mL/min) 75.1 ± 3.6 83.9 ± 5.9 73.8 ± 5.1
Gender (male/female) 7/14 7/15 9/12
Type of resection gastrectomy 4 9 6
proctocolectomy 8 4 7
hepatectomy 2 4 1
pancreatectomy 2 3
cholecystectomy 2 2 1
others 3 3 3The Latent Risk of Acidosis in TPN Products
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study period. No patients suffered from metabolic alkalosis
or acidosis. All patients did not change their body weight
during this study.
The time courses of serum electrolyte levels after
administration of the TPN solutions are shown in Fig. 2.
The concentrations of serum electrolytes such as Na+, K+,
and Cl−, changed slightly but were within normal limits.
There were no significant changes in the concentration of
serum creatinine, BUN, urine electrolytes, and urine
creatinine during this study (data not shown).
The time courses of urine pH and NAE levels after
administration are shown in Figure 3. Urinary pH did not
change in the AMINO and PN groups, but decreased in the
UNI group after administration, whereas urinary NAE
Fig. 1. Time courses of plasma pH, plasma HCO3−, pCO2, and BE levels after administration of AMINO (circle), PN (triangle), and
UNI (square) TPN solutions. Values are mean ± s.e. *p<0.05 vs POD 1. BE; blood base excess, POD: postoperative day.
Fig. 2. Time courses of serum electrolyte levels after administration of AMINO (circle), PN (triangle), and UNI (square) TPN
solutions. Values are mean ± s.e. *p<0.05 vs POD 1.K. Kato et al.
J. Clin. Biochem. Nutr.
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increased significantly in the UNI group after administration.
The time courses of lactic acid and pyruvic acid levels are
shown in Fig. 4. The serum concentration of lactic acid
decreased significantly in the AMINO group at POD 3 and
in the PN group at POD 3 and 7 compared to POD 1. The
serum concentration of pyruvic acid decreased significantly
in the AMINO group at POD 3 and in the PN group on POD
3, 5, and 7 compared to POD 1. There were no significant
changes in the serum concentration of lactic acid or pyruvic
acid in the UNI groups.
Discussion
Acidosis during TPN therapy could be related to the
presence of hydrochloric salts in synthetic L-amino-acid
preparations [5–8]. ASPEN and JSPEN have developed
clinical guidelines for TPN therapy. However, these guide-
lines have not commented on the risk of the acid load
induced from pH adjustment agents in TPN solutions.
Recently, hydrochloric acid has been added to bagged
commercial TPN solutions to avoid Maillard reaction, which
is induced by D-glucose and amino acids, and the UNI
solution uses hydrochloric salts of synthetic L-amino-acid to
avoid this reaction. Organic acids such as acetic acid are
added to the TPN solutions to stabilize the pH of the
products after heat sterilization [13]. Therefore, two types
of acids are added to commercial TPN solutions to maintain
the quality of the formula. As a result, the titratable acidity
of the nutrient solution consists of hydrochloric acid and
organic acids. In general, titratable acidity is higher in
solutions containing hydrochloric salts, and the adjusted
TPN solutions have higher titratable acidity compared to the
standard solutions. Terashima et al. suggested that metabolic
acidosis is caused by the high titratable acidity induced from
not only non-metabolizable acids but also from metabo-
lizable acids in commercial TPN solutions [9]. This study
focused on acids in TPN solutions as a cause of metabolic
acidosis and investigated the effect of non-metabolizable
and metabolizable acids on the plasma acid-base balance.
The present findings suggested that the amount of titratable
acidity is not related to the incidence of acid load. Only non-
metabolizable acids such as hydrochloric acid influence the
patient’s acid load.
Metabolic acidosis is a pH imbalance in which the body
has accumulated too much acid and does not have enough
bicarbonate to effectively neutralize the effects of the acid.
Previously, we reported that the acid load with hydrochloric
acid in TPN solutions may cause severe hyperchloremic
metabolic acidosis in rabbits [11]. In the present study,
urinary pH decreased slightly and NAE increased signifi-
cantly after administration in UNI group, but other two
groups did not change urinary pH and NAE. Urine becomes
Fig. 3. Time courses of urine pH and NAE levels after administration of AMINO (circle), PN (triangle), and UNI (square) TPN
solutions. Values are mean ± s.e. *p<0.05 vs POD 1. NAE; net acid excretion.
Fig. 4. Time courses of serum lactic and pyruvic acid levels after administration of AMINO (circle), PN (triangle), and UNI (square)
TPN solutions. Values are mean ± s.e. *p<0.05 vs POD 1.The Latent Risk of Acidosis in TPN Products
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more acidic when the body is in acidosis. Since urine is a
waste, the acid in the urine are lost for the body and this
contributes to return the body pH to a normal value. However,
there is no regulation that pharmaceutical companies should
indicate the amount of added acid in the attached documents
for their products. This situation is dangerous for physicians
because they cannot determine the risk of acidosis when
they order TPN prescriptions. Therefore, information
regarding the potential inorganic acid content in commercial
TPN solutions should be included in the attached documents
for TPN products.
The present study focused on acids in TPN solutions as a
cause of metabolic acidosis and investigated the effect of
metabolizable and non-metabolizable acids on the plasma
acid-base balance. The present results suggest that the
amount of titratable acidity is not related to the incidence of
acid load. Only non-metabolizable acids such as hydrochloric
acid influence serum pH in patients. Non-metabolizable acid
may be a risk factor of metabolic acidosis. Therefore,
pharmaceutical companies should inform medical profes-
sionals of the amount of non-metabolizable acid in TPN
solutions to help to avoid metabolic acidosis.
Abbreviations
TPN, total parenteral nutrition; NAE, net acid excretion;
CASPjp, Critical Appraisal Skills Programme JAPAN;
BCAA, Branched chain amino acid; BUN, blood urea
nitrogen; TA, titratable acid; BE, base excess; Aminotoripa®,
AMINO; PNtwin®, PN; Unicaliq®, UNI; POD, postoperative
day.
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